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Background: After kidney transplantation, immunosuppressive therapy causes impaired cellular immune defense leading
to an increased risk of viral complications. Trough level monitoring of immunosuppressants is insufficient to estimate the
individual intensity of immunosuppression. We have already shown that virus-specific T cells (Tvis) correlate with control
of virus replication as well as with the intensity of immunosuppression. The multicentre IVIST01-trial should prove that
additional steering of immunosuppressive and antiviral therapy by Tvis levels leads to better graft function by avoidance
of over-immunosuppression (for example, viral infections) and drug toxicity (for example, nephrotoxicity).
Methods/design: The IVIST-trial starts 4 weeks after transplantation. Sixty-four pediatric kidney recipients are randomized
either to a non-intervention group that is only treated conservatively or to an intervention group with additional
monitoring by Tvis. The randomization is stratified by centre and cytomegalovirus (CMV) prophylaxis. In both groups
the immunosuppressive medication (cyclosporine A and everolimus) is adopted in the same target range of trough
levels. In the non-intervention group the immunosuppressive therapy (cyclosporine A and everolimus) is only steered
by classical trough level monitoring and the antiviral therapy of a CMV infection is performed according to a standard
protocol. In contrast, in the intervention group the dose of immunosuppressants is individually adopted according to
Tvis levels as a direct measure of the intensity of immunosuppression in addition to classical trough level monitoring.
In case of CMV infection or reactivation the antiviral management is based on the individual CMV-specific immune
defense assessed by the CMV-Tvis level. Primary endpoint of the study is the glomerular filtration rate 2 years after
transplantation; secondary endpoints are the number and severity of viral infections and the incidence of side effects
of immunosuppressive and antiviral drugs.
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Discussion: This IVIST01-trial will answer the question whether the new concept of steering immunosuppressive and
antiviral therapy by Tvis levels leads to better future graft function. In terms of an effect-related drug monitoring, the study
design aims to realize a personalization of immunosuppressive and antiviral management after transplantation. Based on
the IVIST01-trial, immunomonitoring by Tvis might be incorporated into routine care after kidney transplantation.
Trial Registration: EudraCT No: 2009-012436-32, ISRCTN89806912 (17 June 2009).
Keywords: Kidney transplantation, Immunosuppression, Virus-specific T cells, Personalized immunosuppressive therapy,
Viral infections, Pediatric transplantation, Cytomegalovirus, Antiviral therapy, Over-immunosuppression, Immunomonitoring,
Drug-monitoringBackground
After solid organ transplantation (Tx), immunosuppres-
sive treatment disrupts the individual balance between
virus replication and cellular immune response. This leads
to an elevated risk of severe viral complications due to pri-
mary infection or reactivation (for example, cytomegalo-
virus (CMV), adenovirus (ADV), or herpes-simplex-virus
(HSV)). CMV is known as a major pathogen after kidney
Tx, whereas the importance of ADV and HSV is still un-
clear, especially in children. Because of high costs and se-
vere side effects, antiviral treatment should be restricted
to patients with high risk of viral diseases [1]. Due to miss-
ing appropriate diagnostic methods, the optimal timing of
antiviral therapy/prophylaxis remains a subject for debate.
Virus load and virus serology are insufficient to predict
the individual risk and to decide upon the necessity and
duration of antiviral prophylaxis and therapy. Virus-
specific T cells (Tvis) have been shown to play a significant
role in the control of virus replication. Therefore, they
may serve as a prognostic marker for virus-induced dis-
eases after Tx. Preliminary studies have found that the risk
of post-transplant CMV-induced disease correlated with
the individual number of CMV-Tvis. Reduced frequencies
of CMV-Tvis in transplant recipients are associated with
increased incidence of infectious complications [2-5].
After adult kidney Tx, symptomatic CMV reactivations
are preceded by a decrease in CMV-CD4+ Tvis frequen-
cies and an increase in CMV load [2]. Gamadia and col-
leagues determined the kinetics and characteristics of
CMV-Tvis in the course of primary CMV infections in
adult renal transplant recipients: in asymptomatic individ-
uals the CMV-CD4+ Tvis response preceded the CMV-
CD8+ Tvis response, whereas in symptomatic individuals
the CMV-specific effector memory CD4+ T cell response
was delayed and only detectable after antiviral therapy
[6,7]. Therefore, Tvis may represent a diagnostic tool to
predict the individual risk for virus complications after
solid organ Tx and enable a selective post-transplant
prophylaxis. It has been shown that after Tx – the time of
maximal immunosuppressive therapy – levels of Tvis are
lower than later after Tx. Accordingly it may be speculated
that the amount of Tvis correlates with the extent ofimmunosuppression. Consequently, immunosuppressive
therapy might better be steered by addition of this param-
eter than by measuring blood levels of immunosuppres-
sants alone.
Studies concerning CMV-Tvis after kidney Tx in adult
renal transplant recipients and healthy individuals were
carried out in Homburg (Saar), Germany [2,8,9], in Los
Angeles, USA [4], in Uppsala, Sweden [10] as well as in
Amsterdam, The Netherlands [6,7,11,12] by cytokine flow-
cytometry and tetramer staining. Additionally, Sester and
colleagues compared levels of CMV-Tvis in long-term
kidney, heart and lung transplant recipients [3]. CMV-
Tvis in adult heart recipients were also evaluated in
Stanford, California, USA [5] and in Berlin, Germany [13].
In Duarte, California, USA, La Rosa and colleagues inves-
tigated CMV-Tvis response after adult liver Tx [14].
Concerning ADV-Tvis after solid organ Tx, there are
only a few studies available: in Homburg (Saar), Germany,
the level of ADV-Tvis were investigated in adult renal
transplant recipients and healthy individuals by cytokine
flowcytometry [15]. In Philadelphia, Pennsylvania, USA,
Olive and colleagues analysed ADV-Tvis response of
healthy adults by ELISPOTand flow cytometry [16].
No studies for HSV-Yvis after solid organ Tx have
been conducted to the best of our knowledge.
The only large trial of Tvis in pediatric kidney recipients
has been carried out to evaluate polyoma BK virus-specific
T cells in a cooperation of Italian centers for Pediatric
Nephrology and the department of virology in Basel,
Switzerland [17]. No pediatric studies exist for CMV-,
ADV- or HSV-Tvis after solid organ Tx. Until now, to our
knowledge, no trials have been conducted that base the
adoption of immunosuppressive therapy not only on drug
trough levels but also on the grade of suppression of Tvis.
After solid organ Tx, immunosuppressive treatment
causes an increased risk of severe viral complications.
Monitoring of the grade of immunosuppression is most
often performed by blood levels of immunosuppressants.
Virus load and serology are insufficient to predict the in-
dividual risk of viral infections and to decide on the ne-
cessity and duration of antiviral prophylaxis and therapy.
Tvis have been shown to correlate with control of virus
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pression. Therefore, they may serve as an indicator of
the level of immunosuppression as well as a prognostic
marker for virus-induced diseases after Tx. Using cyto-
kine flow cytometry we are able to monitor Tvis with
specificity for different virus types.
In future this method should be established as routine
use in order to develop new strategies to steer and
individualize immunosuppressive therapy, to avoid se-
vere infections, to improve post-transplant management
of viral infections and to optimize the individual timing
of antiviral therapy.Methods/design
The general aim of the trial is a prolongation of renal
graft function and reduction of viral infections after
kidney Tx by monitoring of Tvis followed by therapeutic
intervention. Therefore, the primary endpoint is the glom-
erular filtration rate (GFR) (cystatin C; Schwartz and Filler
formula) 2 years after Tx. Secondary endpoints are reduc-
tion in viral infections after kidney Tx, optimization of the
individual timing of antiviral therapy, optimization of the
immunosuppressive therapy, reduction of nephrotoxic ef-
fects of cyclosporine A (CsA) and antiviral agents by opti-
mized dosing, and premature study discontinuations due
to adverse events.
According to the legislation, “patients suffering from
rare conditions should be entitled to the same quality of
treatments as other patients” [18]. We interpret this in a
way that randomized evidence for treatment decisions
should be provided. Even if it is clear from the beginning
that it will be difficult to achieve “significant” results at
the end, the randomized comparison is obviously much
less prone to bias than findings from prospective obser-
vational studies, or retrospective comparisons. In conse-
quence the estimators and confidence intervals that will
be calculated from this study will be in every case more
informative than from uncontrolled studies.
Therefore the study was planned as a multicenter,
randomized, open-labeled study recruiting 64 children
during the first 2 years after kidney Tx. This study is
designed to improve the post-transplant steering of
immunosuppressive drugs (CsA and everolimus) and the
post-transplant management of CMV infections by
quantitation of Tvis from whole blood samples. Based
on specific cellular activation and induction of intracel-
lular cytokines the levels of Tvis for different virus types
(CMV, ADV, HSV) will be measured using flow cytome-
try (see below). In the non-intervention group, the im-
munosuppressive therapy is only based on classical
trough level monitoring and the antiviral treatment is
performed according to center practice. In the interven-
tion group, the immunosuppressive and the antiviraltherapy will be additionally adapted to the levels of Tvis.
The study design is summarized in Figures 1 and 2.
Taking into account the importance of appropriate im-
munosuppressive medication after kidney Tx, no placebo
arm will be included in this study. In both the non-
intervention group and the intervention group, the im-
munosuppressive medication (CsA and everolimus) will
be steered in the same ‘usual’ target range of trough levels
due to the standard protocol. In the non-intervention
group the physician arbitrarily decides on the application
rate of the immunosuppressive medication within the de-
fined normal target range of trough levels, whereas in the
intervention group the immunosuppressive medication is
additionally steered by measurement of Tvis levels.
Inclusion/exclusion criteria
A total of 64 male or female children (aged 0 to 16 years)
will be included. They will be enrolled if they meet the
inclusion/exclusion criteria outlined in Table 1.
Patients are randomized in a 1:1 ratio to a treatment
group. The randomization is stratified for CMV prophy-
laxis and center. Due to the open-label nature of this
trial the randomization is performed centrally by the
Department of Biostatistics of the Hannover Medical
School to guarantee that patients are included into the
trial before allocation to the treatment group is commu-
nicated. Patients are randomized in a 1:1 ratio to an
intervention or a non-intervention group.
The time point of study start and randomization is
4 weeks after Tx, when the initial immunosuppressive
therapy (see below) is switched to low-dose CsA and
everolimus combined with low-dose steroids. The im-
munosuppressive therapy is steered in all patients by
classical trough levels of CsA and everolimus. Patients
are randomized to an intervention group with additional
monitoring of Tvis or to a non-intervention group with
only conservative trough level monitoring.
Study drugs
Cyclosporine A
In both study groups patients are treated with CsA;
according to the following schedule: the CsA start dose
is 400 mg/m2 per day in two doses (maximal dose
250 mg); the dose will be adopted to target trough levels
of 140 to 190 ng/ml (by liquid chromatography-mass
spectrometry/mass-spectrometry (LC-MS/MS)) for the
first 4 weeks after Tx. Afterwards, CsA dose will be re-
duced by 50% to a target trough level of 50 to 100 ng/ml
(LC-MS/MS) (a tolerance of ±10% in the target trough
level is allowed for a period of 8 weeks) when adminis-
tered together with everolimus. Target CsA trough levels
are reduced to 30 to 75 ng/ml (a tolerance of ±10% in the
target trough level is allowed for a period of 8 weeks)
6 months after Tx.
Figure 1 Treatment regime. CsA, cyclosporine A.
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mately 12-hour intervals in the morning and in the
evening for the complete study duration of 23 months.
Blood should be drawn within 15 minutes before the
administration of the morning dose of CsA.
Everolimus
In both study groups patients are treated with everoli-
mus, starting 4 weeks after Tx at 1.6 mg/m2 per day in
two doses (maximal dose 1.5 mg). At first, target trough
levels are 3 to 6 ng/ml (LC-MS/MS); 6 months after Tx
the target trough levels are reduced to 2 to 5 ng/ml.
Dosing should be adjusted in all patients if the everoli-
mus whole blood trough level is below 3 ng/ml or above
6 ng/ml (a tolerance of ±10% in the target trough level is
allowed for a period of 8 weeks) and below 2 ng/ml or
above 5 ng/ml (a tolerance of ±10% in the target trough
level is allowed for a period of 8 weeks) 6 months after Tx.
Everolimus is administered simultaneously with CsA
on a twice-daily schedule at approximately 12-hour
intervals in the morning and in the evening for the
complete study duration of 23 months. Blood should
be drawn 15 minutes before the administration of the
morning dose of everolimus.Figure 2 Study design. ADV, adenovirus; CMV, cytomegalovirus;
HSV, adenovirus; Tvis, virus-specific T cells.Valganciclovir
In the intervention as well as in the non-intervention
group, patients at high risk for primary CMV infection
(CMV-seronegative recipients of CMV-seropositive or-
gans) receive an anti-viral prophylaxis. In both groups,
valganciclovir is administered prophylactically in the first
3 post-transplant months in CMV-IgG negative children
who receive a kidney from a CMV-IgG positive donor.
In case of CMV infection or reactivation with relevant
CMV-DNA detection, in both study groups an antiviral
therapy with valganciclovir is started.
The dosing of Valganciclovir is calculated according to
the following: dose (mg) =GFR × 7 × body surface area.
This is applied in one single dose per day (maximum dose
1 × 900 mg). If the calculated GFR exceeds 150 ml/minper 1.73 m2, the dose is calculated with a GFR of 150 ml/
min per 1.73 m2.
Study drug adjustments
Immunosuppressive therapy (cyclosporine A and everolimus)
In the intervention group, the level of CD4+ Tvis (cells/μl)
are detected (see below) in addition to trough level moni-
toring of immunosuppressants. In case of high Tvis levels
(25% above the upper threshold level) the dose of im-
munosuppressive drugs (CsA and everolimus) will be in-
creased 10 to 15%; in case of low Tvis levels (25% below
the lower threshold level) the dose of immunosuppressive
drugs (CsA and everolimus) will be decreased 10 to 15%.
If the CsA or everolimus trough levels have reached the
lower or upper threshold levels given above, no adaptation
of CsA or everolimus doses is performed due to levels of
CD4+ Tvis.
In the non-intervention group, immunosuppressive
medications are only steered by classical trough levels
due to the standard protocol given above.
Antiviral therapy (valganciclovir)
In case of a CMV infection or reactivation with rele-
vant CMV-DNA detection, an antiviral therapy with
Table 1 Selection criteria
Inclusion criteria
1 Patients who are males or non-pregnant females between the ages
of 0 and 16 years.
2 Patients 4 weeks after kidney Tx.
3 Patients who received their first or second Tx 4 weeks ago.
4 Patients who are single-organ recipients.
5 If patients are women of childbearing potential, they must have a
negative serum pregnancy test with a sensitivity equal to at least
50 mIU/ml before Tx.
6 If patients are women of childbearing potential, they must use
an effective form of contraception such as the birth control pill
(except mini-pill), hormonal depot injection, contraceptive hormonal
patches, implanon, contraceptive hormone-containing coil or
hormone-containing contraceptive vaginal ring, unless abstinence is
the chosen method. In case of medical contraindication concerning
the hormonal contraception, an intrauterine coil with a second
contraceptive method (condom, diaphragm, spermicide) can be
used. Effective contraception must be used before Tx, during
therapy, and for 6 weeks following discontinuation of
immunosuppressive therapy.
7 Patients’ guardians must be capable of understanding the
purpose and risks of the study.
8 Patients whose guardians are willing to give written informed
consent and willing to participate in and comply with the study
protocol. Patients above 7 years have to agree with the study in
addition to the informed consent of the legally authorized
representative.
Exclusion criteria
1 Patients participating in other studies or participated within the
last 4 weeks before study start.
2 Patients who are highly sensitized.
3 Patients who have undergone two organ transplantations previous
to the current kidney Tx (that is, two kidney transplantations,
two liver transplantations, kidney and liver, or kidney and
pancreas transplantation).
4 Hypersensitivity to any of the components of the medication used.
5 Patients from other centers who are not followed in the outpatient
unit of the Hannover Medical School or corresponding
participating centers.
6 Patients with a peak or current panel reactive antibodies >50 %.
7 Pregnant and/or lactating women and women of childbearing
potential who are unwilling or unable to use contraception
methods as specified.
8 Patients whose guardians do not understand the requirements
of the study.
9 Patients with known positive HIV-1 or Hepatitis C virus test or
the presence of Hepatitis B surface antigen.
10 Patients with malignancies or history of malignancy, despite
post-transplant lymphoproliferative disease.
11 Patients who are not eligible in the opinion of the physician.
12 Significant medical history and/or treatments for cardiac, renal,
neurological, hepatic, endocrine diseases, or any laboratory
abnormality indicative of a significant underlying condition, that
may interfere with patient’s safety, compliance, or study evaluations,
according to the investigator’s opinion.
Tx, transplantation.
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non-intervention group valganciclovir is given for
3 months. In contrast, in the intervention group the
valganciclovir therapy is carried out until a sufficient
and stable number of CMV-CD4+ Tvis is found and
CMV-DNA is below the detection limit.
Concomitant immunosuppressive treatment
Basiliximab
The total dose of for patients weighing less than 35 kg is
20 mg intravenously, given in two doses of 10 mg each.
For patients weighing 35 kg or more the recommended
total dose is 40 mg intravenously, given in two doses of
20 mg each. The first 10 mg (20 mg) dose should be
given within 2 hours prior to Tx surgery. The second
10 mg (20 mg) dose should be given 4 days after Tx.
Steroids (prednisolone)
On day 0, patients are given 300 mg/m2 in one dose,
and then the following protocol is followed: first week
after Tx, 60 mg/m2 in two doses/day; week 2 after Tx:
30 mg/m2 in two doses/day; week 3 after Tx, 15 mg/ m2
in one dose/day; week 4 after Tx, 12 mg/m2 in one dose/
day; week 5 after Tx, 9 mg/m2 in one dose/day; week 6
after Tx, 6 mg/m2 in one dose/day; thereafter, final dose
of 4 mg/m2 in one dose/day.
Patients without signs of rejection based on a protocol
biopsy 6 months after kidney Tx are eligible for the con-
trolled steroid withdrawal within 3 months. Patients with
pathological changes continue steroid administration.
Study assessments
Patients are seen and evaluated according to the flow
chart given in Table 2. Patients should be encouraged to
return for all evaluations as scheduled. However, a time
window of 3 days for bi-weekly visits and 7 days for (bi)
monthly visits is allowed.
Renal function is assessed by measuring serum cre-
atinine, serum cystatin C, and estimated GFR by the
Schwartz and Filler formula. Quantitative urine albu-
min and creatinine are determined as a measure of
glomerular damage.
In all suspected rejection episodes, regardless of the
initiation of anti-rejection treatment, a biopsy should be
performed within 48 hours in the absence of medical
contraindications. The histological evaluation of the bi-
opsy will be performed locally. A biopsy-proven acute
rejection is defined as a biopsy graded IA, IB, IIA, IIB,
or III for the Banff 2007 classification. A protocol bi-
opsy is performed to evaluate signs of subclinical rejec-
tion at month 6. This biopsy is only counted as protocol
defined if, at this time point, no clinical signs of rejec-
tion are observed.
Table 2 Flow chart of study visits
Week/month (after transplantation) Months 1-3 (±3 days) Months 4-12 (±7 days) Months 13-24 (–7 days)
Week Monthly (except




0 4* 6 8 10 12 6 12 24






Pregnancy test as appropriate2 X
Vital signs (weight, blood pressure, pulse) X X X X X X X X X X
Height X X X X X X X X
Hematology (including differential count) X X X X X X X X X X
Chemistry panel (bilirubine., SGOT, SGPT, yGT, GlDH, CK, LDH)3 X (X) X (X) X
Lipid profile (cholesterol, LDL, HDL, triglycerides) X X X X
Serum creatinine, urea X X X X X X X X X X
Urine analysis (sticks, quantitative urine albumin and creatinine) X X X X X X X X X X
Trough level of CsA4 X X X X X X X X X X
Trough level of everolimus4 X X X X X X X X X X
CMV-, ADV-, HSV-specific T cells5 X X X X X X X X X X
CMV, HSV, EBV IgG, IgM X X X X X X X X X X
CMV, ADV, EBV HSV-PCR X X X X X X X X X X
Clinical assessment X X X X X X X X X
Protocol biopsy X X X X X X X
CsA half dose and start everolimus X X X X X X X
Start of steroid elimination X X X X X X X
Treatment of rejection6 X X X X X X X (X) (X) (X)
Prior/concomitant medications X X X X X X X X X X
Adverse events X X X X X X X X X X X
*Study start. 1Confirmation of informed consent prior to study start. 2Results must be available before study start. 3Chemistry panel is performed every 4 months.
4Levels at indicated time points will be documented on case report form (CRF) summary pages. 5Results at indicated time points will be documented on CRF
summary page, analysis will be performed at Hannover Medical School; determination only in the intervention group. 6For all rejection episodes, a core renal
biopsy should be performed; results of the biopsy and treatment of rejection will be documented in the medical record and recorded on the CRF. ADV,
adenovirus; CK, creatine kinase; CMV, cytomegalovirus; CsA, cyclosporine A; EBV, Epstein-Barr virus; GIDH Glutamate dehydrogenase; HDL, high-density lipoprotein;
HSV, herpes-simplex-virus; Ig, immunoglobulin; LDH; LDL, low-density lipoprotein; PCR, polymerase chain reaction; SGOT, serum glutamic oxaloacetic transaminase;
SGPT, serum glutamic pyruvic transaminase; yGT, gamma-glutamyl-transferase.
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decline in renal function and is typically preceded by the
histological picture of chronic allograft nephropathy. The
presence of biopsy confirmed grade I, II, or III chronic
allograft nephropathy by the Banff 2007 criteria is assessed
on all optional biopsies obtained for clinical suspicion of
chronic rejection.
Height is determined at baseline and monthly after the
study start. Blood pressure will be measured at each visit
and all antihypertensive medication is documented with
a start and end date.At each visit indicated in the assessment schedule,
CMV-, ADV-, HSV-, and Epstein-Barr virus (EBV)-DNA
as well as viral serology are determined. Analysis of the
blood samples will be analyzed in each center in collabor-
ation with the corresponding local laboratories. Active in-
fections with CMV, EBV, ADV, HSV or other viruses are
recorded with a start and end date.
In the intervention group, the number of CMV-, ADV-
and HSV-Tvis are determined via cytokine flow cytometry
at each visit indicated in the assessment schedule. Analysis
of Tvis levels is performed at the Hannover Medical School.
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The method identifies CD4+ T cells in which cytokine
production is stimulated by virus antigens. The analysis of
Tvis is performed in four steps from heparinized whole
blood:
1. Stimulation: blood leukocytes are stimulated by virus
antigen. Costimulatory antibodies (CD28 and
CD49d) are added to maximize the detection of T
lymphocytes with a higher activation threshold. This
leads to induction of intracellular cytokine
production as IFNγ and TNFα. Cytokine production
(IFNγ and TNFα) by Tvis is visualized by the use of
Brefeldin A that inhibits granule secretion and leads
to intracellular accumulation of cytokines. As a
negative control, an antigen that contains no
virus-specific antigen is used. The positive control is
performed by Staphylococcus aureus enterotoxin B.
2. Fixation: erythrocytes are lysed and lymphocytes are
fixed and washed.
3. Immunostaining: activated T lymphocytes are
marked by fluorescent antibodies binding at CD4,
CD69 and IFNγ or TNFα.
4. Fluorescence-activated cell sorting procedure: the
percentage of fluorescence-marked lymphocytes is
measured by flow cytometry. CD69-positive and
IFNγ/TNFα-positive CD4+ T lymphocytes represent
the virus-specific CD4+ T cells (CD4+ Tvis).Figure 3 Fluorescence-activated cell sorting analysis of virus-specific
FITC Fluorescein; FSC (forward scatter; IFN, interferon; SSC sideward scatter.By fluorescence-activated cell sorting analysis, the per-
centage of CD4+ T cells is measured that were successfully
stimulated by viral antigens. The activation of T cells leads
to upregulation of CD69 and intracellular production of
cytokines (for example, IFNγ and TNFα) as shown in
Figure 3.
Statistical methods
The primary objective of this trial is to demonstrate a
prolongation of renal graft function and (as a key sec-
ondary objective) a reduction of the number of severe
viral infections/reactivation after kidney Tx by monitor-
ing Tvis followed by therapeutic intervention. Renal
function will be measured at each visit by GFR.
The primary analysis will be conducted on the
intention-to-treat population. All analyses are based on
two-sided hypotheses using a significance level of 5%. The
precise primary hypothesis of the study is that the GFR
24 months after kidney Tx is significantly larger in the
intervention group compared to the non-intervention
group and will be tested by an analysis of covariance. The
primary analysis model consists of the GFR 24 months
after Tx as the dependent variable. Treatment strategy, in-
cluding the intervention and the control treatment, a cov-
ariable including patient’s baseline GFR and two other
factors (the CMV prophylaxis (yes/no) and the center) are
used for stratification purposes. The estimate, as well as
the two-sided 95% confidence interval, for the differenceT cells (Tvis). An example of cytomegalovirus (CMV)-Tvis is shown.
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primary endpoint will be provided from the analysis of co-
variance model. Superiority will be concluded if the lower
boundary of this confidence interval is larger than 0. Differ-
ences in the number of viral infections will be analyzed
using a generalized linear model based on the negative bi-
nomial distribution. As soon as the primary hypothesis can
be rejected, the reduction in the number of viral infections
will be assessed as a confirmatory analysis.
Furthermore, secondary analyses will investigate the
treatment effect in the strata of CMV prophylaxis and
the center. In addition, interaction between treatment
strategy and the CMV prophylaxis will be investigated
descriptively.Sample size and power considerations
The clinical hypothesis is that GFR values 24 months
after kidney Tx will be higher in the intervention group
compared to the non-intervention group.
Due to the orphan condition under investigation, sample
size calculation is feasibility driven and describes under
which circumstances this trial can be formally successful.
The total sample size of this study is limited to 64 pa-
tients; that is, 32 patients per treatment group. The effect
of the therapy is considered as relevant if the difference be-
tween the therapy groups in mean GFR is at least 7.5 ml/
min per 1.73 m2 with a standard deviation of 15 ml/min
per 1.73 m2. With these assumptions, the power to reject
the null hypothesis of no difference between treatment
groups with a two-sided t-test for two independent samples
and a significance level of 5% (two-sided) is 50%. To reach
a power of 80% in the same setting, a treatment effect of
10.672 ml/min per 1.73 m2 has to be achieved. It is as-
sumed that stratification for CMV prophylaxis and center
and adjustment for patient’s baseline will lead to an increase
in power.Ethics statement
The study was approved by the ethics committee of
Hannover Medical School (reference number 5067 M) as
the leading center and the Bundesinstitut für Arzneimittel,
as well as by the ethics committee of the University of
Cologne, the Medical Board of Hamburg and the University
of Rostsock as secondary committees who reported to the
leading committee. A data safety monitoring committee
(DSMC) has been implemented from the beginning of the
trial consisting of a pediatric pulmonologist, a transplant
surgeon and an adult nephrologist. The DSMC meets on a
yearly basis and has suggested continuing with the trial
until now.
Informed consent is obtained from all participating
patients and their parents.Discussion
After kidney Tx, trough level monitoring of immunosup-
pressants is insufficient for individualized steering of
immunosuppressive therapy and leads to over- und
under-immunosuppression. In a prospective, multicenter,
randomized controlled study, the IVIST01-trial will test the
hypothesis that additional steering of immunosuppressive
and antiviral therapy by Tvis levels will improve renal graft
function and survival by individualizing post-transplant
management and avoiding over-immunosuppression and
drug toxicity. This novel concept of immunomonitoring by
Tvis might optimize future steering of immunosuppressive
and antiviral therapy and thereby become an important
step towards personalized immunosuppressive and antiviral
therapy in terms of an effect-related drug monitoring.
Trial status
A total of 35 patients from two centers have been re-
cruited (status as of 1 July 2014); 20 patients have finished
the study, five patients became drop-outs (one patient in
the control group died by drowning in the bath tub). All
safety reports suggest continuing the trial as planned. Re-
cruitment was slower than originally intended; therefore,
the study was changed from a monocenter to a multicen-
ter trial in 2012. Actually half of the anticipated patient
numbers have been reached. The first additional center
has started recruitment. With the two additional centers
starting to recruit patients, the end of recruitment can be
estimated for 2015.
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